Ignyta, Inc. is a biotechnology company. The Company is focused on precision medicine in oncology. The Company is pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. The Company's pipeline includes various compounds, such as entrectinib, RXDX-105, taladegib and RXDX-106. Entrectinib is an orally bioavailable, central nervous system (CNS)-active, small molecule tyrosine kinase inhibitor directed to the tropomyosin receptor kinase (TRK) family of tyrosine kinase receptors (TRKA, TRKB and TRKC), ROS1 and anaplastic lymphoma kinase (ALK) proteins. RXDX-105 is an orally bioavailable, vascular endothelial growth factor receptor (VEGFR)-sparing, small molecule tyrosine kinase inhibitor of rearranged during transfection (RET). Taladegib is an orally bioavailable, small molecule hedgehog/smoothened antagonist. RXDX-106 is a pseudo-irreversible, small molecule inhibitor of TYRO3, AXL and MER (collectively TAM), and c-MET.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:RXDX
CUSIPN/A
Phone+1-858-2555959
Debt
Debt-to-Equity Ratio0.34
Current Ratio6.07
Quick Ratio6.07
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.28 per share
Price / Book11.82
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-103,630,000.00
Net MarginsN/A
Return on Equity-113.09%
Return on Assets-68.72%
Miscellaneous
Employees112
Outstanding Shares67,590,000
Market Cap$1.79 billion
Ignyta (NASDAQ:RXDX) Frequently Asked Questions
What is Ignyta's stock symbol?
Ignyta trades on the NASDAQ under the ticker symbol "RXDX."
How were Ignyta's earnings last quarter?
Ignyta Inc (NASDAQ:RXDX) announced its quarterly earnings data on Tuesday, November, 7th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.03. View Ignyta's Earnings History.
What price target have analysts set for RXDX?
5 Wall Street analysts have issued twelve-month price objectives for Ignyta's stock. Their predictions range from $20.00 to $31.00. On average, they anticipate Ignyta's stock price to reach $26.40 in the next year. This suggests that the stock has a possible downside of 2.0%. View Analyst Price Targets for Ignyta.
What is the consensus analysts' recommendation for Ignyta?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ignyta in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Ignyta.
What are Wall Street analysts saying about Ignyta stock?
Here are some recent quotes from research analysts about Ignyta stock:
- 1. Cantor Fitzgerald analysts commented, "The merger was announced on December 22, 2017, and the transaction was completed on February 8, 2018." (2/9/2018)
- 2. According to Zacks Investment Research, "Ignyta, Inc. is a biotechnology company. It develops precision medicine with integrated Rx/Dx solutions for cancer patients. The company focuses on the development of RXDX-101, its proprietary oral tyrosine kinase inhibitor that targets solid tumor indications, and advancing its novel Spark discovery programs that leverage its proprietary cancer genomic and epigenomic knowledge bases. Ignyta, Inc. is based in San Diego, California. " (1/17/2018)
Who are Ignyta's key executives?
Ignyta's management team includes the folowing people:
- Jonathan E. Lim M.D., Chairman of the Board, President, Chief Executive Officer, Co-Founder (Age 45)
- Jacob M. Chacko M.D., Chief Financial Officer (Age 38)
- Zachary Hornby, Chief Operating Officer (Age 38)
- Valerie Harding Start Ph.D., Senior Vice President - Chemistry, Manufacturing, and Controls (Age 57)
- Christian V. Kuhlen M.D. Esq., General Counsel, Secretary (Age 44)
- William R. McCarthy, Chief Business Officer (Age 45)
- Pratik S. Multani M.D., Chief Medical Officer (Age 50)
- James A. Bristol Ph.D., Independent Director (Age 70)
- Alexander W. Casdin, Independent Director (Age 49)
- Heinrich Dreismann Ph.D., Independent Director (Age 64)
Has Ignyta been receiving favorable news coverage?
News headlines about RXDX stock have been trending somewhat positive on Monday, according to Accern. The research group identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Ignyta earned a news and rumor sentiment score of 0.20 on Accern's scale. They also assigned media coverage about the biopharmaceutical company an impact score of 46.66 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. View Recent Headlines for Ignyta.
How do I buy shares of Ignyta?
Shares of RXDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ignyta's stock price today?
One share of RXDX stock can currently be purchased for approximately $26.95.
How big of a company is Ignyta?
Ignyta has a market capitalization of $1.79 billion. Ignyta employs 112 workers across the globe.
How can I contact Ignyta?
Ignyta's mailing address is 4545 Towne Centre Ct, SAN DIEGO, CA 92121-1900, United States. The biopharmaceutical company can be reached via phone at +1-858-2555959.
MarketBeat Community Rating for Ignyta (NASDAQ RXDX)
MarketBeat's community ratings are surveys of what our community members think about Ignyta and other stocks. Vote "Outperform" if you believe RXDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RXDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
